RxDoctor Payments Data

Oscar Perez Gutierrez, MD

Internal Medicine · Lake Mary, FLNPI 1174059885

Payments from drug & device makers

$1,048in general payments, 2019–2025

Across 67 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$320
  • Pfizer$103
  • Boehringer Ingelheim$82
  • Abbott$76
  • Amgen$75
  • Merck$69
  • plus $325 from 12 others

What the payments were for

  • Speaking & faculty fees$81%
  • Food & beverage$1,04199%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,048 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$42,521
Medicare patients
183
Services billed
390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide118$126,571
OzempicSemaglutide93$99,115
JardianceEmpagliflozin82$79,203
MounjaroTirzepatide54$64,809
FarxigaDapagliflozin Propanediol45$36,299
SantylCollagenase Clostridium Hist.22$26,636
EliquisApixaban26$24,188
JanumetSitagliptin Phos/Metformin Hcl23$21,737
TradjentaLinagliptin13$19,159
XareltoRivaroxaban14$15,699
Diclofenac Sodium121$15,433
JanuviaSitagliptin Phosphate21$11,455
Advair HfaFluticasone Propion/Salmeterol26$8,291
Varenicline Tartrate35$7,816
Repatha SureclickEvolocumab11$7,231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$320$225,685211 claims
Boehringer IngelheimJardiance, Tradjenta$82$98,36295 claims
Lilly USA, LLCMounjaro$44$64,80954 claims
AstraZenecaFarxiga$28$36,29945 claims
MerckJanumet, Januvia$69$33,19244 claims
PfizerEliquis$103$24,18826 claims
GSKBreo Ellipta$32$6,60617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Lake Mary

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →